Loading…
← CockpitCompetitor Analysis › 3378.HK Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class HOpen in the cockpit ↗

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H3378.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum weak 28
Mkt cap
$409M
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$66,017
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-48.6 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · HKDHK$22.00
1D-4.3%
1W-13.7%
1M-19.2%
3M-24.9%
6M-23.5%
YTD+37.7%
1Yn/a
ATR %7.1%
52w lowhigh34.9% off high

What Hanx Biopharmaceuticals (Wuhan) does

Employees: 64

Hanx Biopharmaceuticals (Wuhan) at a glance

Size Hanx Biopharmaceuticals (Wuhan) (3378.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $409M, the 801st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$22.00 on 18 Nov 2026.

Performance Over six months the shares fell 23.5%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.

Capital Return on invested capital runs 48.6 points below its cost of capital (5.6% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 773378.HK 73
Six months, rebased to 100: Hanx Biopharmaceuticals (Wuhan) against the median of its 20 peers (local-currency closes).

Hanx Biopharmaceuticals (Wuhan) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$0HK$0HK$0HK$0HK$0
Revenue growth—————
Gross profit-HK$7.84M-HK$6.94M-HK$5.94M-HK$1.15M-HK$1.01M
EBITDA-HK$152M-HK$135M-HK$125M-HK$69.6M-HK$86.8M
Net income-HK$146M-HK$142M-HK$126M-HK$84.0M-HK$33.0M
Free cash flow-HK$94.2M-HK$114M-HK$117M-HK$57.6M-HK$53.4M
Capital expenditureHK$460,289HK$2.11MHK$6.73MHK$5.28MHK$998,912
Total debtn/aHK$62.2MHK$153MHK$16.5MHK$459,201

Quarterly statements and history in the cockpit →

Hanx Biopharmaceuticals (Wuhan) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%69986882381167EPRX688163456160688098CADL4768306883172480300683654767122509688687PRTAPNV30096617893378.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Hanx Biopharmaceuticals (Wuhan) is the large dot.

Hanx Biopharmaceuticals (Wuhan) competitors and peer comparison

How Hanx Biopharmaceuticals (Wuhan) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hanx Biopharmaceuticals (Wuhan) against its 20 peers (data as of 18 Nov 2026)
Measure3378.HKPeer medianRank in peer set
1-month return-19.2%-11.3%5th lowest of 21
6-month return-23.5%-22.0%10th lowest of 21
Distance from 52-week high-34.9%-41.5%5th highest of 21
ROIC minus cost of capital-48.6 pp-7.4 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%

Questions

Which companies are Hanx Biopharmaceuticals (Wuhan)'s closest peers?
The cockpit's peer set: Edding Genor (6998.HK), Shanghai Obio Technology (Group) (688238.SS), Jacobio Pharmaceuticals (1167.HK), Eupraxia Pharmaceuticals (EPRX.TO), Shanghai Serum Bio-Technology (688163.SS), G2GBIO (456160.KS), Shanghai Shen Lian Biomedical (688098.SS), Candel Therapeutics (CADL).
How has Hanx Biopharmaceuticals (Wuhan) stock performed?
Over six months to 18 Nov 2026 the shares returned -23.5% against -22.0% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.